Literature DB >> 34815519

Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.

Nobuhiko Imahashi1, Seitaro Terakura2, Eisei Kondo3, Koji Kato4, Sung-Won Kim5, Akihito Shinohara6, Mizuki Watanabe7, Takahiro Fukuda5, Naoyuki Uchida8, Hikaru Kobayashi9, Jun Ishikawa10, Keisuke Kataoka11,12, Souichi Shiratori13, Takashi Ikeda14, Ken-Ichi Matsuoka15, Shuro Yoshida16, Tadakazu Kondo7, Takafumi Kimura17, Makoto Onizuka18, Tatsuo Ichinohe19, Yoshiko Atsuta20,21, Junya Kanda7.   

Abstract

We retrospectively compared the outcomes of reduced-intensity conditioning (RIC) transplantation from matched related donors (MRD; n = 266), matched unrelated donors (MUD; n = 277), and umbilical cord blood (UCB; n = 513) for mature lymphoid malignancies. The 3-year overall survival rates for the MRD, MUD, and UCB groups were 54%, 59%, and 40%, respectively (P < 0.001). Multivariate analysis showed no differences in survival between the MRD group and the MUD or UCB group. However, survival was significantly affected by the conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in the UCB group, but not in the MRD and MUD groups. Notably, multivariate analysis showed that the risk of overall mortality in the UCB recipients who received the optimal conditioning regimen and GVHD prophylaxis (n = 116) was lower than that in the MRD group (relative risk [RR], 0.69; P = 0.03) and tended to be lower than that in the MUD group (RR, 0.75; P = 0.09). Our results suggest that UCB transplantation performed with the optimal conditioning regimen and GVHD prophylaxis is highly effective. Moreover, UCB is readily available. Thus, UCB transplantation with the optimal conditioning regimen and GVHD prophylaxis is preferable to MUD transplantation when MRD are not available in the setting of RIC transplantation for mature lymphoid malignancies.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34815519     DOI: 10.1038/s41409-021-01525-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  22 in total

1.  Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data).

Authors:  Yoshiko Atsuta
Journal:  Int J Hematol       Date:  2015-11-07       Impact factor: 2.490

2.  Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Carmen Martínez; Jorge Gayoso; Carmen Canals; Hervé Finel; Karl Peggs; Alida Dominietto; Luca Castagna; Boris Afanasyev; Stephen Robinson; Didier Blaise; Paolo Corradini; Maija Itälä-Remes; Arancha Bermúdez; Edouard Forcade; Domenico Russo; Michael Potter; Grant McQuaker; Ibrahim Yakoub-Agha; Christof Scheid; Adrian Bloor; Silvia Montoto; Peter Dreger; Anna Sureda
Journal:  J Clin Oncol       Date:  2017-08-28       Impact factor: 44.544

3.  Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

Authors:  Navneet S Majhail; Daniel J Weisdorf; John E Wagner; Todd E Defor; Claudio G Brunstein; Linda J Burns
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

4.  PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Authors:  Peter Dreger; Anna Sureda; Kwang Woo Ahn; Mary Eapen; Carlos Litovich; Herve Finel; Ariane Boumendil; Ajay Gopal; Alex F Herrera; Christoph Schmid; José Luis Diez-Martin; Ephraim Fuchs; Javier Bolaños-Meade; Mahasweta Gooptu; Monzr M Al Malki; Luca Castagna; Stefan O Ciurea; Alida Dominietto; Didier Blaise; Fabio Ciceri; Johanna Tischer; Paolo Corradini; Silvia Montoto; Stephen Robinson; Zafer Gülbas; Mehdi Hamadani
Journal:  Blood Adv       Date:  2019-02-12

5.  Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System.

Authors:  Yoshiko Atsuta; Ritsuro Suzuki; Ayami Yoshimi; Hisashi Gondo; Junji Tanaka; Akira Hiraoka; Koji Kato; Ken Tabuchi; Masahiro Tsuchida; Yasuo Morishima; Makoto Mitamura; Keisei Kawa; Shunichi Kato; Tokiko Nagamura; Minoko Takanashi; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

6.  Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Authors:  Nilanjan Ghosh; Reem Karmali; Vanderson Rocha; Kwang Woo Ahn; Alyssa DiGilio; Parameswaran N Hari; Veronika Bachanova; Ulrike Bacher; Parastoo Dahi; Marcos de Lima; Anita D'Souza; Timothy S Fenske; Siddhartha Ganguly; Mohamed A Kharfan-Dabaja; Tim D Prestidge; Bipin N Savani; Sonali M Smith; Anna M Sureda; Edmund K Waller; Samantha Jaglowski; Alex F Herrera; Philippe Armand; Rachel B Salit; Nina D Wagner-Johnston; Ephraim Fuchs; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

7.  Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.

Authors:  Celso Arrais Rodrigues; Vanderson Rocha; Peter Dreger; Claudio Brunstein; Henrik Sengeloev; Jürgen Finke; Mohamad Mohty; Bernard Rio; Eefke Petersen; François Guilhot; Dietger Niederwieser; Jan J Cornelissen; Pavel Jindra; Arnon Nagler; Nathalie Fegueux; Hélène Schoemans; Stephen Robinson; Annalisa Ruggeri; Eliane Gluckman; Carmen Canals; Anna Sureda
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

8.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

Review 9.  Transplant strategies in relapsed/refractory Hodgkin lymphoma.

Authors:  Gunjan L Shah; Craig H Moskowitz
Journal:  Blood       Date:  2018-03-02       Impact factor: 25.476

10.  Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status.

Authors:  Le Zhang; Yi-Zhuo Zhang
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.